EUNETWORKS/LUMENISITY
14.4.2021 10:02:15 CEST | Business Wire | Press release
euNetworks Fiber UK Limited (“euNetworks”), a Western European bandwidth infrastructure company, has deployed their first ultra low latency CoreSmart® cable solution based on NANF® hollowcore fibres. Lumenisity® Limited (“Lumenisity”) supplied the CoreSmart® cable solution, with this new deployment now live between Interxion: A Digital Realty Company, and the London Stock Exchange. This is the first commercially available deployment of this technology in the world and is part of an agreement covering additional deployments over the coming years between trading venues and other locations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005248/en/
Data travels 50% faster in hollowcore cable, reducing latency by 1/3, and providing a round trip saving of 3μs per km. These latency savings are very significant in financial trading applications. They can also be scaled to increase the separation of data centres by 50%, whilst maintaining the latency envelope, more than doubling the area of land in which these data centres can be located. With deployments in numerous private networks over the last three years, Lumenisity's CoreSmart® is the lowest loss, broadest bandwidth hollowcore cable available commercially.
euNetworks leads the market in delivering fibre-based ultra low latency services throughout Europe. Its euTrade solution is a dedicated network platform supporting the bandwidth needs of the financial services community. The company continues to optimise routes between all the key trading exchanges in Europe to ensure delivery of the shortest paths and lowest latencies available in the market.
“We’re very pleased to partner with euNetworks to enable them to provide the lowest latency performance to a major trading exchange using our CoreSmart® cable,” said Tony Pearson, Business Development Director at Lumenisity. “We are excited to be collaborating with such an established Carrier and to already have hollowcore deployed, carrying traffic as part of this development.”
“We continue to focus on delivering lowest latency services for our customers. We focus on identifying new and innovative technologies that can be deployed on our network to provide the best possible bandwidth solutions,” said Brady Rafuse, Chief Executive Officer of euNetworks. “We’re excited to be working with Lumenisity, helping to develop and deploy hollowcore fibre. We’re confident that with this technology we can achieve market leading fibre-based latencies much closer to radio frequency systems, without the constraints that are inherently present with those radio frequency solutions.”
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 51 cities in 15 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 440 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com .
About Lumenisity® Limited
Lumenisity®
Limited was formed in early 2017 as a spin out from the University of Southampton to commercialise breakthroughs in the development of hollowcore optical fibre. The company has built a team of industry leaders and experts to realise their goal to be the world’s premier high-performance hollowcore fibre optic cable solutions provider offering their customers reliable, deployable, low latency and high bandwidth connections that unlock new capabilities in communication networks. Lumenisity®, NANF® and CoreSmart® are registered trademarks of Lumenisity Limited.
Visit their website at: www.lumenisity.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005248/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 15:00:00 CEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 15:00:00 CEST | Press release
The FME creator is recruiting for more than 60 roles across the UK, US and Canada before the end of December, less than a year after crossing $100M in revenue Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software.
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom